Infantile Beriberi Presenting as Subacute Necrotizing Encephalomyelopathy
J Pediatr 110:888-892, Wyatt,D.T.,et al, 1987
Radiation-Induced Bilateral Oculomotor Nerve Palsy 20 Years After Radiation Treatment
Neurol 96:955-957, Grassmeyer, J.J.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Severe Cutaneous Candida Infection During Natalizumab Therapy in Multiple Sclerosis
Neurol 74:521-523, Gutwinski,S.,et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor Study
J Natl Cancer Inst 101:946-958, Armstrong,G.T.,et al, 2009
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Thrombolysis-Related Intracranial Hemorrhage, Analysis of 224 Cases from GUSTO-1 Trial with Clin Correl
Stroke 29:563-569, Gebel,J.M.,et al, 1998
Progressive Deterioration of Intellect and Motor Function Occurring Several Decades after Cranial Irradiation
ARch Neurol 53:814-818, Duffey,P.,et al, 1996
Intracerebral Hemorrhage After Fibrinolytic Therapy for Acute Myocardial Infarction
C. R. , Stroke 24:554-557, 5233., Wijdicks,E.F.M.&Jack,Jr, 1993
Intracranial Hemorrhage After Coronoary Thrombolysis with Tissue Plsminogen Activator
Am J Med 92:384-390, Kase,C.S.,et al, 1992
CT patterns of Intracranial Hemorrhage Complicating Thrombolytic Therapy for Acute Myocardial Infarction
Radiology 181:555-559, Uglietta,J.P.,et al, 1991
The Effect of Radiation of Carotid Arteries, A Review Article
Arch Neurol 46:449-455, Murros,K.E.&Toole,J.F., 1989
Striatal Syndrome Following Hyponatremia & Its Rapid Correction, Extrapontine Myelinolysis by MRI
Arch Neurol 45:112-114, Dickoff,D.J.,et al, 1988
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Stroke-Like Migraine Attacks After Radiation Therapy Syndrome
Neurol 104:e210203, Lubotzky,A.,t al, 2025
Postprocedural Brachial Neuritis:Clinical, Electrodiagnostic, and Neuroimaging Features
AJNR 46:1050-1055, Ambati,V.S.,et al, 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
GLP-1RA-Associated Diabetic Lumbosacral Radiculoplexus and Common Fibular Neuropathies
Neurol 105:e213916, Triplett,J.D.,et al, 2025
Frequency, Risk Factors, and Outcomes of Strokes in Patients with Primary Glioma After Cranial Radiation
Neurol 105:e213902, Ryan,D.,et al, 2025
The Multifactorial Nature of Ischemic Stroke in Malignancy
Stroke 56:e303-e306, Doyle,C.L.,et al, 2025
Neurovascular Complications of Iatrogenic Fusarium solani Meningitis
NEJM 390:522-529, Strong, N.,et al, 2024
Risk of Stroke and Myocardial Infarction Among Initiators of Triptans
JAMA Neurol 81:248-254, Petersen,C.L.,et al, 2024
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Blook Transfusion and Brain Amyloidosis, Should We Be Worried?
JAMA 330:921-922, Greenberg,S.M., 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Imaging Findings in Children Presenting with CNS Nelarabine Toxicity
AJNR 43:1802-1809, Serrallach,B.L.,et al, 2022
Chorioretinopathy After Corticosteroid Treatment for Optic Neuritis
Neurol 96:e305-e306, Ling, J. and Micieli, J.A., 2021
Clinicopathologic Conference, Fat Embolism Syndrome
NEJM 385:2464-2474, Case 39-2021, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Looking Beyond the Usual
Delhi J Ophthal doi:7869/djo.555, Shakrawal, J.,et al, 2020